Nicotine Conjugate Vaccine as a Novel Approach to Smoking Cessation

Anne R. Ottney, Pharm.D


Pharmacotherapy. 2011;31(7):703-713. 

In This Article

Economic Considerations

The financial impact of tobacco-related illness on both a national and global level is significant. In the United States, #96 billion/year in health care costs are spent for treating tobacco-related illnesses.[24] Many of the available drug therapies for smoking cessation are approximately equal in price to smoking one pack of cigarettes/day. To our knowledge, no projected cost of the 3′-AmNic-rEPA vaccine has been disclosed. Results from a recent health statistics survey show that approximately 40% of smokers have an annual household income of less than #35,000, making provision of the vaccine at a reasonable cost key to the acceptance of the vaccine, considering the large number of adults who are smokers living at or below the federal poverty line.[25]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.